Skip to main content
. 2016 May 17;9:2911–2917. doi: 10.2147/OTT.S102472

Table 3.

RR and DCR of icotinib for patients with BMs from lung adenocarcinoma

Total (N=28) Treatment-naïve patients (n=11) Retreated patients (n=17) Patients with EGFR gene mutations (n=12) Patients with unknown EGFR gene status (n=16)
RR (%) 67.8 81.8 91.7 91.7 50.0
DCR (%) 96.4 90.9 100.0 100.0 93.8

Abbreviations: RR, remission rate; DCR, disease control rate; BMs, brain metastases; EGFR, epidermal growth factor receptor.